NewsBenzingaEton Pharmaceutical annuncia il nuovo programma di sviluppo ET-900 che valuta l’iniezione di mecasermin per il trattamento degli spasmi infantili ed epilettici; prevede di somministrare la prima dose al primo paziente nel primo trimestre del 2027 Eton Pharmaceutical annuncia il nuovo programma di sviluppo ET-900 che valuta l’iniezione di mecasermin per il trattamento degli spasmi infantili ed epilettici; prevede di somministrare la prima dose al primo paziente nel primo trimestre del 2027 Benzinga 2026.11.02 11:52 (GMT+0) Open on Benzinga Other news Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings Stifel Reinstates Buy on Walmart, Announces $145 Price Target HC Wainwright & Co. Reiterates Buy on Perpetua Resources, Maintains $43.5 Price Target Stifel Reinstates Hold on Target, Announces $155 Price Target WW International Intends To Utilize Up To $10M In Cash To Prepay Portion Of Outstanding Term Loan At Discount Through Voluntary Solicitation Of Offers From Term Loan Lenders
Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report
WW International Intends To Utilize Up To $10M In Cash To Prepay Portion Of Outstanding Term Loan At Discount Through Voluntary Solicitation Of Offers From Term Loan Lenders